Interleukin-27 subunit beta (IL-27 subunit beta) (IL-27B) (Epstein-Barr virus-induced gene 3 protein) (EBV-induced gene 3 protein)
1_MTPQL 6_ LLALV 11_ LWASC 16_ PPCSG 21_ RKGPP 26_ AALTL 31_ PRVQC 36_ RASRY 41_ PIAVD 46_ CSWTL 51_ PPAPN 56_ STSPV 61_ SFIAT 66_ YRLGM 71_ AARGH 76_ SWPCL 81_ QQTPT 86_ STSCT 91_ ITDVQ 96_ LFSMA 101_ PYVLN 106_ VTAVH 111_ PWGSS 116_ SSFVP 121_ FITEH 126_ IIKPD 131_ PPEGV 136_ RLSPL 141_ AERQL 146_ QVQWE 151_ PPGSW 156_ PFPEI 161_ FSLKY 166_ WIRYK 171_ RQGAA 176_ RFHRV 181_ GPIEA 186_ TSFIL 191_ RAVRP 196_ RARYY 201_ VQVAA 206_ QDLTD 211_ YGELS 216_ DWSLP 221_ATATM
1: Associates with IL27 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines